UPCC 17518: A Phase 1 First-in-Human Open-Label Dose Escalation Study of MGD013 A Bispecific DART Protein binding PD-1 and LAG-3 in Patients with Unresectable or Metastatic Neoplasms
Enrolling By Invitation
99 years or below
All
Phase
1
10 participants needed
1 Location
Brief description of study
The primary objective of this study is to characterize the safety, tolerability, dose limiting toxicities (DLTs), and maximum tolerated dose (MTD) or maximum administered dose (MAD) (if no MTD is defined) of MGD013 when
administered intravenously (IV) every 2 weeks to patients with unresectable, locally advanced or metastatic cancers.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: TBD
-
Age: 99 years or below
-
Gender: All
Updated on
04 Aug 2024.
Study ID: 832205
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
